Kintara Therapeutics Inc logo

Kintara Therapeutics Inc

NAS:KTRA (USA)  
$ 0.10 +0.0125 (+13.97%) 02:44 PM EST
At Loss
Enterprise V:
$ 13.09M
Volume:
29.29M
Avg Vol (2M):
12.11M
Also Trade In:
Volume:
29.29M
At Loss
Avg Vol (2M):
12.11M

Business Description

Description
Kintara Therapeutics Inc is engaged in the development of novel cancer therapies for patients with unmet medical needs. The company is developing two late-stage, Phase 3-ready therapeutics for clear unmet medical needs with reduced risk development programs. The two programs are VAL-083 for GBM and REM-001 for CMBC. VAL-083 is a small-molecule chemotherapeutic with a novel mechanism of action that has demonstrated clinical activity against a range of cancers, including the central nervous system, ovarian, and other solid tumors. The company operates within a single operating segment the research and development of cancer indications, and operates primarily in one geographic area, being North America.

Financial Strength

Name Current Vs Industry Vs History
Cash-To-Debt No Debt
Equity-to-Asset -0.09
Interest Coverage No Debt
Piotroski F-Score 2/9
0
1
2
3
4
5
6
7
8
9
WACC vs ROIC
WACC
ROIC

Momentum Rank

Name Current Vs Industry Vs History
5-Day RSI 41.45
9-Day RSI 43.64
14-Day RSI 42.4
6-1 Month Momentum % -97.62
12-1 Month Momentum % -97.24

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 0.63
Quick Ratio 0.63
Cash Ratio 0.35

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -94.7
Shareholder Yield % -75.1

Profitability Rank

Name Current Vs Industry Vs History
ROE % -592.94
ROA % -220.52
ROIC % -1104.97
ROC (Joel Greenblatt) % -1104.97
ROCE % -549.12

GF Value Rank

Name Current Vs Industry Vs History
EV-to-EBIT -1.23
EV-to-EBITDA -1.24
EV-to-Forward-Revenue 0.85
EV-to-FCF -1.93
Earnings Yield (Greenblatt) % -81.3
FCF Yield % -169.99

Financials (Next Earnings Date:2024-05-14 Est.)

KTRA's 30-Y Financials
Income Statement Breakdown
No Enough Data
Balance Sheet Breakdown
No Enough Data
Cashflow Statement Breakdown
No Enough Data

Historical Operating Revenue by Business Segment

Historical Operating Revenue by Geographic Region

5-Step DuPont Analysis as of
No Enough Data

Guru Trades

See Details
To

Insider Trades

See Details
To

Gurus Latest Trades with NAS:KTRA

No Available Data

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To

Performance

Dividend
Log
Bar
To

Annualized Return %  

Symbol
1 Week
1 Month
3 Months
6 Months
YTD
1 Year
3 Years
5 Years
10 Years

Total Annual Return %  

Symbol
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015

Kintara Therapeutics Inc Executives

Details

GF Value

Valuation Chart

Year:

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil $)
EPS (TTM) ($) -5.96
Beta -0.08
Volatility % 109.11
14-Day RSI 42.4
14-Day ATR ($) 0.010791
20-Day SMA ($) 0.094575
12-1 Month Momentum % -97.24
52-Week Range ($) 0.081 - 5.98
Shares Outstanding (Mil) 39.04

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 2
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Kintara Therapeutics Inc Filings

Filing Date Document Date Form
No Filing Data

Kintara Therapeutics Inc Stock Events

Financials Calendars
Event Date Price($)
No Event Data

Kintara Therapeutics Inc Frequently Asked Questions

What is Kintara Therapeutics Inc(KTRA)'s stock price today?
The current price of KTRA is $0.10. The 52 week high of KTRA is $5.98 and 52 week low is $0.08.
When is next earnings date of Kintara Therapeutics Inc(KTRA)?
The next earnings date of Kintara Therapeutics Inc(KTRA) is 2024-05-14 Est..
Does Kintara Therapeutics Inc(KTRA) pay dividends? If so, how much?
Kintara Therapeutics Inc(KTRA) does not pay dividend.

Press Release

Subject Date
No Press Release

Headlines

See More
  • 1
No news.
  • 1